Jakub Marczak

Jakub Marczak

Auto-generated profile, based on publicly available information

Jakub Marczak

Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in General Physiology and Biophysics
Verified
Journal Article
Closed access
IKIwona Kaminska
Iwona Kaminska
MKMalgorzata Kotulska
Malgorzata Kotulska
ASAnna Stecka
Anna Stecka
JSJolanta Saczko
Jolanta Saczko
MDMalgorzata Drag-Zalesinska
Malgorzata Drag-Zalesinska
Julita KulbackaJulita Kulbacka
Julita Kulbacka
Electroporation-induced changes in normal immature rat myoblasts (H9C2)

1 January 2011 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
APA. Pupka
A. Pupka
JSJ. Skora
J. Skora
DJD. Janczak
D. Janczak
TPT. Plonek
T. Plonek
JMJ. Marczak
J. Marczak
TST. Szydełko
T. Szydełko

3 December 2017 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
SASleiman Sebastian Aboul-Hassan
Sleiman Sebastian Aboul-Hassan
TSTomasz Stankowski
Tomasz Stankowski
JMJakub Marczak
Jakub Marczak
MPMaciej Peksa
Maciej Peksa
MNMarcin Nawotka
Marcin Nawotka
RCRomuald Cichon
Romuald Cichon

26 January 2012 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
JMJakub Marczak
Jakub Marczak
RNRafał Nowicki
Rafał Nowicki
Julita KulbackaJulita Kulbacka
Julita Kulbacka
JSJolanta Saczko
Jolanta Saczko
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether remote ischaemic preconditioning (RIPC) is of benefit to patients undergoing cardiac surgery. Altogether, more than 264 papers were found using the reported search, 16 of which represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that RIPC is a safe protocol which could potentially be used in cardiac surgery to provide additional cardiac protection against ischaemia reperfusion injury, although it may not be appropriate for patients on K+ ATPase channel blockers (sulphonylureas) as they seem to eliminate the effect of RIPC. In our study, we found two meta-analyses of cardiac surgery with or without RIPC. Both unequivocally showed 0.81 and 0.74 standardized mean reduction in myocardial necrosis markers in patients receiving RIPC and cardiac or vascular surgery. No difference in perioperative myocardial infarction incidence or 30-day mortality were found. In adult cardiac surgery, we found 11 randomized control trials (RCTs) ranging in size from 45 to 162 patients. Two representative studies reported no difference in postoperative cardiac troponin I concentration in RIPC vs. controls. In one of the studies (CABG ± RIPC) no additional benefit could have been observed for RIPC regarding intra-aortic balloon pump usage (controls 8.5 vs. RIPC 7.5%), inotropic support (39 vs. 50%) or vasoconstrictor usage (66 vs. 64%). On the other hand, in the other study [CABG ± AVR (aortic valve replacement) ± RIPC] significant reduction of troponin I at 8 h postoperatively (controls, 2.90 µg/l vs. RIPC, 2.54 µg/l, P = 0.043) was shown. Marked reduction in cardiac necrosis markers was also found in several smaller RCTs concerning coronary artery bypass grafting (CABG) patients receiving RIPC preoperatively: with cold crystalloid cardioplegia (44.5% reduction), with cross-clamping and fibrillation (43% reduction) and with cold blood cardioplegia (42.4% reduction). The proof of concept trials summarized here give some early evidence that RIPC may potentially provide some reduction in myocardial injury. If confirmed, in future clinical studies this technique may one day lead to a method to reduce reperfusion injury in clinical practice.

9 July 2015 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
TSTomasz Stankowski
Tomasz Stankowski
SASleiman Sebastian Aboul-Hassan
Sleiman Sebastian Aboul-Hassan
JMJakub Marczak
Jakub Marczak
RCRomuald Cichon
Romuald Cichon
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether thoracoscopic patent ductus arteriosus (PDA) closure is superior to conventional surgery. Altogether 821 papers were found using the reported search, 11 of which represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Eleven studies included in the analysis consisted of two prospective and three retrospective, non-randomized studies and six case series. Four included studies focused only on preterm infants, three studies enrolled neonates and the other four analysed all age groups from neonates to older children or young adults. There were no differences in mortality between video-assisted thoracoscopic surgery (VATS) and conventional surgery. Two studies suggested that VATS offers shorter operative times. Two papers observed shorter hospital stay, although the other two noted no significant difference. A large prospective trial found VATS to be associated with a lower number of postoperative complications in neonates and infants, whereas other studies suggested no significant differences in short-term postoperative complications. There is little evidence to suggest better musculoskeletal status and cosmesis in neonates following VATS. Conversion from thoracoscopy to thoracotomy described in six papers was seldom and it did not lead to any additional complications. All observational studies confirmed that both techniques are free from major adverse cardiovascular complications and these two techniques can be safely used in all patients qualified for surgical PDA closure. Two studies compared cost-effectiveness between the two techniques; one of them described VATS as significantly more cost-efficient, whereas the other study observed no difference. However, it should be noted that data were provided from different countries and time periods. The results presented suggest that there are no significant differences in early clinical outcomes between VATS and thoracotomy in all age groups. However, where differences have been shown, such as pain, postoperative complications, length of hospital and ICU stay and cost, these favour the VATS approach.

29 August 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
MNMarta Negrusz-Kawecka
Marta Negrusz-Kawecka
RPRafał Poręba
Rafał Poręba
AHAnna Hulok
Anna Hulok
KŚKrzysztof Ściborski
Krzysztof Ściborski
JMJakub Marczak
Jakub Marczak
TBTomasz Bańkowski
Tomasz Bańkowski
Cystatin C is a novel marker used in the diagnosis of preclinical chronic kidney disease (CKD). The aim of the study was to assess the role of cystatin C in the diagnosis of coronary artery disease. The study involved 63 patients of a mean age of 62.7 ± 9.5 years. The population was divided into two groups: Group I were patients with angiographically diagnosed coronary artery disease (CAD) with their first acute coronary syndrome (ACS, n = 45); Group II were patients who had clinically diagnosed coronary disease but were negative on angiography (n = 18). Cystatin C levels were measured before angiography in both groups; in Group I they were also measured 6 months after discharge. Cystatin C levels were significantly higher in Group I (p = 0.01), and this depended on the type of CAD: non-ACS, non-ST elevated myocardial infarction (NSTEMI) or ST elevated myocardial infarction (STEMI) (p = 0.01). Cystatin C levels correlated inversely with the left ventricular ejection fraction in the whole study population (p = 0.003) and in patients with NSTEMI (p = 0.03). A high cystatin C level was found to be a risk factor for ACS (OR: 1.002 95% CI [1.00029-1.004], p = 0.02) and STEMI (OR: 1.0009 95% CI [0.99-1.002], p = 0.04) but not for NSTEMI (OR: 0.99 95% CI [0.99-1.0], p = 0.21. A ROC analysis revealed that there is a significantly higher risk of ACS above a cystatin C level of 727.85 ng/mL (OR: 5.5 CI [1.65-18.3], p = 0.004) and a significantly higher risk of STEMI above 915.22 ng/mL (OR: 5.9 CI [1.7-19.7], p = 0.003). The available data suggest that a high cystatin C level is a risk factor for ACS and STEMI. This could play an important role in the early diagnosis and prevention of adverse cardiovascular events.